SCHEDULE: Morgan Stanley Reduces Rigel Pharma Stake Below 5%

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported ceasing to be beneficial owners of more than five percent of Rigel Pharmaceuticals Inc.'s common stock.

Summary

• Morgan Stanley and Morgan Stanley Capital Services LLC filed an Amendment No. 1 to Schedule 13G for Rigel Pharmaceuticals Inc. common stock.
• The filing indicates that as of September 30, 2025, Morgan Stanley and its subsidiary have ceased to be beneficial owners of more than five percent of Rigel Pharmaceuticals Inc.'s common stock.
• Morgan Stanley beneficially owns an aggregate of 116,406 shares, representing 0.7% of the class.
• Morgan Stanley Capital Services LLC beneficially owns an aggregate of 71,545 shares, representing 0.4% of the class.
• Morgan Stanley Capital Services LLC is a wholly-owned subsidiary of Morgan Stanley.

Sentiment

Score: 4

Explanation: The reduction of a significant institutional stake by Morgan Stanley is generally perceived as a negative signal, suggesting a potential decrease in investor confidence or a strategic portfolio adjustment by a major holder.

Negatives

• A significant institutional investor, Morgan Stanley, has reduced its beneficial ownership in Rigel Pharmaceuticals Inc. below the 5% threshold, which could be perceived as a decrease in institutional support.

Industry Context

This filing represents a routine disclosure of a change in institutional ownership, where a major financial institution has reduced its stake in a publicly traded pharmaceutical company. Such changes are closely watched by the market as they can signal shifts in investor sentiment or portfolio strategy.

Stakeholder Impact

• Shareholders: The reduction in a significant institutional holding may lead to increased scrutiny of the company's prospects and potentially influence share price.

Key Dates

Recommendation

The reduction of Morgan Stanley's beneficial ownership below the 5% threshold for Rigel Pharmaceuticals Inc. is a notable event. While not necessarily indicative of fundamental issues with Rigel, it signals a major institutional investor has reduced its position. Investors should 'hold' and re-evaluate their positions, seeking further information on Rigel's operational performance, strategic initiatives, and broader market sentiment to understand the implications of this institutional divestment.

Keywords

Rigel Pharmaceuticals, Morgan Stanley, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Ownership